Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Viatris Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $31.12, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Viatris Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $573.00 | $17.86 |
52-Week Low | $14.60 | $9.49 |
Market Cap | — | $19.09B |
Enterprise Value | — | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU, a US stock, trades at $33.31, down 8.64% in the last 24 hours. Technical indicators show a bullish trend with strong moving averages, while oscillators are neutral. The company recently executed a 10:1 reverse stock split and declared a $0.29 dividend for H2-2026. Key support and resistance levels are at $30 and $36, respectively.
The outlook for MSTU is mixed; bullish technicals contrast with negative media sentiment highlighting significant past value erosion. Risks include high volatility and leveraged ETF decay. Investors should weigh technical strength against fundamental uncertainties and sentiment concerns before considering a position.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
